Evidence map›Paper›PMID 20010945›Full record

ReviewBritish journal of cancer2010

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors.

N Murukesh, C Dive, G C Jayson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011
    Trial
  15. Trial
  16. Trial
  17. Review
  18. Review
  19. Article
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

N MurukeshDepartment of Medical Oncology, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Cancer Research UK and University of Manchester, Wilmslow Road, Withington, Manchester M20 4BX, UK.
C Dive
G C Jayson

Funding

Medical Research Council G0601746Medical Research Council G0902173
6 · The paper itself

Abstract

Vascular endothelial growth factor (VEGF) has been confirmed as an important therapeutic target in randomised clinical trials in multiple disease settings. However, the extent to which individual patients benefit from VEGF inhibitors is unclear. If we are to optimise the use of these drugs or develop combination regimens that build on this efficacy, it is critical to identify those patients who are likely to benefit, particularly as these agents can be toxic and are expensive. To this end, biomarkers have been evaluated in tissue, in circulation and by imaging. Consistent drug-induced increases in plasma VEGF-A and blood pressure, as well as reductions in soluble VEGF-R2 and dynamic contrast-enhanced MRI parameters have been reported. In some clinical trials, biomarker changes were statistically significant and associated with clinical end points, but there is considerable heterogeneity between studies that are to some extent attributable to methodological issues. On the basis of observations with these biomarkers, it is now appropriate to conduct detailed prospective studies to define a suite of predictive, pharmacodynamic and surrogate response biomarkers that identify those patients most likely to benefit from and monitor their response to this novel class of drugs.

Indexed as

Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntineoplastic AgentsBevacizumabBiomarkersBlood PressureCell HypoxiaContrast MediaDrug Delivery SystemsEndothelial CellsHumansMagnetic Resonance ImagingNeoplasmsNeovascularization, PathologicAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntineoplastic AgentsBevacizumabBiomarkersContrast MediaReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID20010945
PMCPMC2813747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.